CDNA CareDx, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1217234 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.9%
TTM net income YoY111.7%
TTM EPS YoY85.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin23.4%
Net margin25.9%
FCF margin—
EBITDA margin27.0%
Returns
ROE33.0%
ROA24.0%
ROIC (approx.)53.4%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $379.81M | $333.79M |
| R&D expense | $71.43M | $72.51M |
| SG&A expense | $107.56M | $125.14M |
| Operating income | -$30.78M | $40.77M |
| Pretax income | -$21.08M | $52.86M |
| Income tax | $271,000 | $310,000 |
| Net income | -$21.35M | $52.55M |
| EBITDA | -$15.76M | $54.96M |
| EPS (basic) | -0.40 | 1.00 |
| EPS (diluted) | -0.40 | 0.93 |
| Weighted avg. shares (diluted) | 53.29M | 56.62M |
| Balance sheet | ||
| Cash & equivalents | $65.43M | $115.27M |
| Short-term investments | $111.78M | $145.96M |
| Receivables | $42.63M | $64.61M |
| Inventory | $26.70M | $19.50M |
| Current assets | $257.13M | $351.83M |
| PP&E, net | $32.97M | $33.55M |
| Goodwill | $40.34M | $40.34M |
| Intangibles | $31.96M | $38.18M |
| Total assets | $413.23M | $491.05M |
| Current liabilities | $89.85M | $89.37M |
| Total liabilities | $110.13M | $112.62M |
| Shareholders' equity | $303.10M | $378.43M |
| Shares outstanding | 50.92M | 54.77M |
| Cash flow statement | ||
| Operating cash flow | $42.03M | $38.05M |
| Investing cash flow | $2.16M | -$483,000 |
| Financing cash flow | -$93.39M | -$5.61M |
| Depreciation & amortization | $15.02M | $14.19M |
| Stock-based compensation | $34.86M | $66.41M |
| Share buybacks | $87.77M | $522,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.